Asian Tech Press (Dec 22) -- Fosun Pharm and BioNTech SE will supply their mRNA COVID-19 vaccine to resident German citizens in China.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma", 02196: HK) and German company BioNTech SE announced Thursday that approximately 11,500 doses of Fubitai for resident German citizens in China, arrived in Beijing on December 21, 2022.

Fubitai or BNT162b2, is a mRNA COVID-19 vaccine developed by Fosun Pharma in collaboration with BioNTech SE.

The batch of vaccines specifically includes Fubitai bivalent vaccine against Omicron BA.4/BA.5 strains and Fubitai monovalent vaccine.

The two companies said they expect to provide vaccination services for resident German citizens in Beijing, Shanghai, Guangzhou, Shenyang and Chengdu with the Fubitai mRNA COVID-19 vaccine.